echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > PLoS One: a new method for rapid detection of celiac antibody

    PLoS One: a new method for rapid detection of celiac antibody

    • Last Update: 2019-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    December 3, 2019 / BIOON / -- recently, researchers at the University of Helsinki developed a novel diagnostic method, called RFs (rapid FRET serum diagnosis), which is used to rapidly measure antibodies in patient samples in the field This technology can completely change the current situation of serodiagnosis of microorganism, autoimmune and allergic diseases Now, the researchers have applied the new concept to the diagnosis of celiac disease, which most patients do not understand (image source: www Pixabay Com) celiac disease is an autoimmune disease, usually with nonspecific gastrointestinal symptoms It affects about 1% of the world's population and more than 90% of its patients are undiagnosed Even in rich countries, more than half of patients do not know their condition Delayed diagnosis and treatment will lead to the decline of quality of life and the continuous occurrence of symptoms As a result, doctors recommend screening for celiac disease: gastrointestinal symptoms or other autoimmune diseases, as well as celiac patients and their first-degree relatives Screening tests involve the measurement of disease-specific antibodies from blood samples In the study, researchers collected abdominal samples of 70 patients from the Kuopio University Hospital, half from children and half from adults The authors also collected control samples from healthy donors The researchers used a new method to measure samples and compared the results with the two currently used methods "The current popular method involves transporting samples to a central laboratory in steps that take hours With the new method, the results can be obtained in less than half an hour just by mixing the sample and reagent mixture, waiting for a while and reading the results The performance of the test is comparable to that of the current method " Dr juuso rusanen, the author of the paper, explained: "we hope that our rapid approach can reduce the threshold of screening for celiac disease, thereby helping to overcome the widespread underdiagnosis of this relatively common disease In addition, this is the first time the new method has been used in the diagnosis of autoimmune diseases This is a promising result and has led to the development of similar tests for the diagnosis of other autoimmune diseases " Information sources: new method enables East and fast detection of cellular disease antibodies original sources: juuso rusanen, Anne Toivonen, Jussi hepojoki, satu hepojoki, Pekka arikoski, Markku Heikkinen, outI vaarala, Jorma ilonen, Klaus Hedman Lfret, a new rapid asset for anti tissue transglutaminase antibodie detection PLoS One, 2019; 14 (11): e0225851 DOI: 10.1371/journal.pone.0225851
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.